1Jia L,Long S,Fu M,et al.Relationship between total cholesterol/hish-density lipoprotein cholesterol ratio.triglyceride/high-density lipoprotein cholesterol ratio,and high-density lipoprotein subclasses[J].Metabolism,2006,55(9):1141-1148.
2Merouani A,Levy E,Mongeau JG,et al.Hyperlipidemic profiles during remission in childhood idiopathic nephritic syndrome[J].Clin Biochem,2003,36(7):571-574.
3Tadashi S,Kaiui L,Nosratola DV.Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis[J].Kidney Intern,2002,61(1):157-162.
4Osama AG,Mohamed AS,Kefaia EM,et al.Impact of treatment of dyslipidemia on renal function,fat deposits and scarring in patients with persistent NS[J].Nephron,2002,91(4):612-619.
5Holmes KW,Kwiterovich PO Jr.Treatment of dyslipidemia in children and adolescents[J].Curt Cardiol Rep,2005,7(6):445-456.
6Brian WM.Hyperlipidemia in children[J].Thromb Res,2006,118(1):49-58.
7Prescott WA Jr,Streetman DA,Streetman DS.The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome[J].Ann Pharmacother,2004,38(12):2105-2114.
8Derosa G,Cicero AE,Bertone G,et al.Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia,type 2 diabetes mellitus,and coronary heart disease:a 12-month,randomized,doubleblind,controlled trial[J].Clin Ther,2004,26(10):1599-1607.
9Brian WM.Hyperlipidemia in children[J].Thromb Res,2006,118:49-58.
10Ruggenenti P,Mise N,Pisoni R,et al.Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies[J].Circulation,2003,107(4):586-592.
